Barbara Shapiro, MD
Neurology · Cleveland, OHNPI 1154301505
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.1% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 8 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $105 and has fallen 54.4% since, to $48 in 2025. That places this record below the midpoint for neurology clinicians in OH, where the typical reported total is $970.
Across 10 payments — averaging $16.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$29
- Sanofi$28
- Takeda Pharmaceuticals U.S.A., Inc.$28
- Johnson & Johnson$20
- Grifols USA, LLC$17
- Catalyst Pharmaceuticals, Inc.$16
- plus $26 from 2 others
What the payments were for
- Food & beverage$15393%
- Education$117%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 2 | $29 |
| Sanofi | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Johnson & Johnson | 1 | $20 |
| Grifols USA, LLC | 1 | $17 |
| Catalyst Pharmaceuticals, Inc. | 1 | $16 |
| Advanced Respiratory, Inc | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$164 in reported general payments places this provider in the 25th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammakedImmune Globul G/Gly/Iga Avg 46 | 13 | $213,647 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 12 | $62,626 |
| Gabapentin | 12 | $775 |
| Pyridostigmine Bromide | 11 | $497 |
Paid to pharmacies, not to this prescriber.
Other neurology in Cleveland
- Imad NajmCleveland$373K
- Hesham AbboudCleveland$363K
- Robert BermelCleveland$302K
- Eric BaronCleveland$297K
- Robert FoxCleveland$296K
- Aarushi SunejaCleveland$269K
- Mary WillisCleveland$254K
- Benjamin WalterCleveland$210K
- Aasef ShaikhCleveland$186K
- Maryann MaysCleveland$173K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.